The Clinical Study on Pseudo-allergic Reaction to Anesthetic Drugs During General Anesthesia

Sponsor
Central South University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03157180
Collaborator
(none)
200
1
24
8.3

Study Details

Study Description

Brief Summary

Perioperative anaphylactic reactions are immediate, hypersensitive reactions that are potentially life-threatening resulting from a sudden release of mediators from mast cells and basophiles. Which is due to either immune (IgE or non-IgE mediated) or non-immune mechanisms. Pseudo-allergic are defined as those reactions that produce the same clinical symptoms with anaphylaxis but are not IgE mediated, occur through a direct nonimmune-mediated release of mediators from mast cells and/or basophils or result from direct activation.so pseudo-allergic reactions do not require previous contact with the substance. Recent studies have shown that a mast-cell-specific receptor,G-protein-coupled receptor MRGPRX2,is crucial for pseudo-allergic drug reactions.in this study. In the study, we will examine the MRGPRX2 gene in patients with pseudo-allergic reactions during anesthesia, aiming at clarifying the relationship between pseudo-allergic reactions and MRGPRX2 gene.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Many of the drugs in general anaesthesia can elicit adverse drug reactions which fall apart into two major types. First, reactions that are usually dose-dependent and related to the pharmacological properties of the drug and/or its metabolites. Second, reactions that are unrelated to the drug's pharmacological characteristics and that are less dose-dependent. These reactions comprise drug intolerance, idiosyncratic reactions and drug-induced immune-mediated allergic and nonimmune-mediated so-called pseudo-allergic. The degree of severity varies and does not allow differentiation between an IgE-mediated or non- IgE mediated reaction resulting from nonspecific mediator release. The incidence of perioperative anaphylactic reactions varies from region, there is no relevant literature about the incidence of perioperative drug allergies in China.in other countries this varies widely between 1/1700 and 1/20000. The mortality from these reaction is in the range from 3 to 6%, and an additional 2% of patients experience significant residual brain damage. A French multi-centre study show NMBAs are the most common agents, being the most frequently involved substances, ranging between 50 and 70%, followed by latex (12-16.7%), and in recent reports, by antibiotics (15%).

    Benjamin et al found in their experiments that members of all NMBD families (except succinylcholine) and the fluoroquinolone family of antibiotics activated mast cells in an Mrgprb2(the orthologue of the human G-protein-coupled receptor MRGPRX2)-dependent manner at concentrations as low as 0.5% of the clinical injection concentration. They determine that MRGPRX2 are targets of many small-molecule drugs associated with systemic pseudo-allergic reactions. In our study, patients with general anesthesia in Xiangya hospital of Central South University were selected as the subjects. Patients with anaphylaxis during anesthesia and has signed an informed consent were selected to extract MRGPRX2 gene exon sequences from blood specimen. The patient's general information and allergy information were then collected .After 4-6 weeks, we will conduct a skin test on suspicious drugs for patients who have undergone allergic reactions. The aim of this study was to explore the relationship between pseudo-allergic reaction and MRGPRX2 gene, and to find out the characteristics of perioperative allergic reaction in our hospital.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    The Clinical Study on Pseudo-allergic Reaction to Anesthetic Drugs During General Anesthesia
    Actual Study Start Date :
    Apr 1, 2017
    Anticipated Primary Completion Date :
    Apr 1, 2019
    Anticipated Study Completion Date :
    Apr 1, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    Test group

    general anesthesia There is allergic reaction during anesthesia Sign informed consent

    Control group

    general anesthesia There is no allergic reaction during anesthesia Sign informed consent

    Outcome Measures

    Primary Outcome Measures

    1. Gene sequence [6 weeks]

      Biobanking of blood from patients with allergic reactions or no allergic reactions (control group) in general anesthesia at xiangya hospital

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • general anesthesia There is allergic reaction during anesthesia Sign informed consent
    Exclusion Criteria:
    • general anesthesia There is no allergic reaction during anesthesia Sign informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Central South University Xiangya Hospital Changsha Hunan China 410013

    Sponsors and Collaborators

    • Central South University

    Investigators

    • Study Director: Wangyuan Zou, Central South University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Wangyuan Zou, Associate Clinical Professor, Central South University
    ClinicalTrials.gov Identifier:
    NCT03157180
    Other Study ID Numbers:
    • 201703781
    First Posted:
    May 17, 2017
    Last Update Posted:
    May 17, 2017
    Last Verified:
    May 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 17, 2017